A Study of DER 45-EV Gel to Treat Rosacea

Completed · Phase 2

Conditions studied: Rosacea

In brief

To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.

Key facts

Study ID

NCT00940992

Run by

Sol-Gel Technologies, Ltd.

People needed

92

Starts

2012-01-01

Expected to finish

2013-01-01

Last updated by the study team

2015-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females, 18 years of age or older
• Facial rosacea, with 12 or more inflammatory lesions (with no more than 2 nodules)
• Mild, Moderate or Severe (2, 3 or 4) rating of rosacea on the IGA
• Females of child-bearing potential must have negative urine pregnancy test result at baseline and must be willing to use an effective form of contraception throughout the study

You may not qualify if…

• Subjects who are pregnant, breast feeding, or planning a pregnancy during the study
• Allergy or sensitivity to ingredients in test product
• Any dermatological conditions of the face that may interfere with study evaluations
• Subjects unable to avoid or minimize exposure to factors that may exacerbate or trigger rosacea

Where it is running

• Baumann Cosmetic & Research Institute — Miami, Florida, United States
• FXM Research Corp — Miami, Florida, United States
• Augusta Centre for Dermatology and Skin — Augusta, Georgia, United States
• Minnesota Clinical Study Center — Fridley, Minnesota, United States
• Skin Search of Rochester, Inc — Rochester, New York, United States
• Tennessee Clinical Research Center — Nashville, Tennessee, United States
• DermResearch, Inc — Austin, Texas, United States
• J & S Studies, Inc — College Station, Texas, United States
• Premier Clinical Research — Spokane, Washington, United States
• Madison Skin and Research, Inc — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.